Egypt’s Metabolic disorders drugs market size stood at USD xx billion in 2019 and is projected to reach USD xx billion by 2028, exhibiting a CAGR of xx% during the forecast period.
The metabolic disorders drugs market consists of sales of metabolic disorders drugs and related services by entities (organizations, sole traders, and partnerships) that produce metabolic disorders drugs to treat metabolic diseases.
In 2017, among the world’s 20 most populous countries, Egypt had the highest age-standardized rate of all diet-related deaths and DALYs. Diabetes and abdominal obesity prevalence in Egypt are high compared to global levels, but low compared with some MENA countries, particularly the Gulf Cooperation Council. The IDF estimates that 14.9% of the adult population in Egypt is currently diagnosed with diabetes and that USD219 was the mean annual diabetes-related spending per person in 2016.
The rise in sedentary jobs, busy lifestyles, and changing consumer preferences are affecting the disease profile of developing countries such as Egypt, especially non-communicable diseases such as diabetes and obesity. Long working hours, less physical activity, and unhealthy eating and drinking habits are major causes of metabolic disorders. These factors are expected to increase the patient pool, thereby driving the metabolic disorders drugs market during the forecast period in Egypt.
The IDF estimates that in 2016, there were 3.2mn cases of diabetes in adults that were undiagnosed. This is a concern, as there are numerous medical complications from diabetes, leading to considerable indirect healthcare costs. In 2016, diabetes accounted for 481,031 DALYs in Egypt, which is set to increase by 2030 to 879,976. The high prevalence of Metabolic Syndrome among middle-aged and elderly Egyptians with the documented high prevalence of chronic diseases in Egypt provides a place for market growth of metabolic drugs.
The presence of several approved metabolic disorders therapeutics drugs and increase in research and development activities and favorable government policies are considered a positive indicator for the growth of metabolic disorders therapeutics.
It is assumed that the market for metabolic disorders therapeutics is majorly hampered by the discontinuation of drugs coupled with stringent regulation procedures.